遗传性血管发作按需治疗:患者报告的利用,障碍和结果
Sandra Christiansen1, Maeve O'Connor2, Timothy Craig3
1Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California.
概括
遗传性血管 (HAE) 发作的按需治疗延迟是常见的,通常是由于治疗焦虑. 这种延迟显著加剧了HAE攻击的严重程度和持续时间,增加了疾病负担.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性血管 (HAE) 是一种罕见的遗传性疾病,其特征是经常出现的发作.
- 这些攻击可以影响身体的各个部位,包括脸部,四肢和呼吸道,造成严重的健康风险.
研究的目的:
- 为了检查对HAE攻击的按需 (OD) 治疗的实际时间.
- 为了确定及时启动OD治疗的障碍.
- 评估延迟治疗对HAE攻击结果的影响.
主要方法:
- 对12岁及以上的HAE (I或II型) 患者进行了一项调查.
- 参与者报告了他们最近的HAE攻击,详细介绍了治疗时间和感知到的障碍.
- 从接受治疗和未接受治疗的攻击队伍中收集了数据.
主要成果:
- 很大一部分患者推迟了OD的使用,只有26%的患者在一小时内接受治疗.
- 79%的人报告了与治疗相关的焦虑,与治疗延迟相关.
- 延迟治疗导致发作的严重程度增加,持续时间更长 (2.7天而不是0.7天),并扩散到其他部位.
结论:
- 在被认为的早期治疗和实际的OD给药时间之间存在着显著的差距.
- 与治疗相关的焦虑是及时管理HAE的一个关键障碍.
- 低于最佳的HAE攻击管理加剧了疾病负担,突出了改善干预和支持的需要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
453
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
453
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
473
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
473


